Anthracyclines chemistry and biology /

Table of Contents: “…Pt.1: Biological occurence and Biosynthesis: Naturally occuring anthracyclines/H. Laatsch, S. Fotso -- Biosynthetic anthracycline variants/J. …”

Razoxane and Dexrazoxane - Two Multifunctional Agents : Experimental and Clinical Results

Connect to this title online

Drugs Affecting Growth of Tumours

Table of Contents: “…Antimetabolites -- DNA-intercalators — the anthracyclines -- Topoisomerase inhibitors -- Tubulin interacting agents -- Vaccination therapies in solid tumors -- Oral anticancer agents -- Anti-angiogenesis agents -- Signal transduction inhibitors -- Endocrine therapy of breast cancer.…”
Connect to this title online

Molecular therapy of breast cancer classicism meets modernity by Lacroix, Marc, 1963-

Table of Contents: “…Introduction -- Selective estrogen receptor modulators (SERMs) and down-regulators (SERDs) -- Aromatase inhibitors -- Agents inducing ovarian suppression -- Antimetabolites -- Alkylating agents -- Anthracyclines -- Microtubule-binding agents -- Topoisomerase inhibitors -- HER family inhibitors -- Angiogenesis inhibitors -- Insulin-like growth factor-I receptor (IGF-1R) inhibitors -- Ras-Raf-MEK-ERK pathway inhibitors -- Ubiquitin-proteasome system inhibitors -- Histone deacetylases inhibitors -- Mitotic inhibitors -- Inhibitors of heat-shock proteins 90 and 27 -- PI3K/Akt/mTOR pathway inhibitors -- Cyclooxygenase-2 inhibitors -- Poly(ADP-Ribose) polymerase (PARP)-1 inhibitors -- Tumor-induced osteolysis inhibitors -- Vaccines and immunomodulators -- Varia.…”
Available online from ProQuest Ebook Central - Academic Complete: 2009

Current Advances in Osteosarcoma Clinical Perspectives: Past, Present and Future

Table of Contents: “…Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective -- Part 1: Surgical Considerations and Outcomes -- Limb Salvage and Reconstruction Options in Osteosarcoma -- Advances in the functional assessment of patients with sarcoma -- Part II: Novel Therapeutic Approaches Based on Biology -- Radiopharmaceuticals for Treatment of Osteosarcoma -- HER-2 Targeted Therapy in Osteosarcoma -- Aerosolized Chemotherapy for Osteosarcoma -- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma -- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease -- Using liquid biopsy in the treatment of patient with osteosarcoma -- Part III: Novel Immunotherapeutic Approaches -- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020’s -- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma -- Natural Killer Cell Immunotherapy for Osteosarcoma -- Nanocapsule delivery of IL-12 -- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy -- Part IV: Survivorship and Late Effects -- Editorial Comments on late effects -- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention -- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors -- Index.…”
Available online from Springer Nature Combo (SCELC)

Advances in Mitochondrial Medicine

Table of Contents: “…Dysfunction of mitochondrial respiratory chain complex I in neurological disorders: genetics and pathogenetic mechanisms -- 18. Anthracyclines and mitochondria -- Section IV-  Applications of Mitochondrial science -- 19. …”
Connect to this title online

Lead optimization for medicinal chemists pharmacokinetic properties of functional groups and organic compounds by Dörwald, Florencio Zaragoza

Table of Contents: “…Alkanes ; Alkenes and alkynes ; Arenes ; Halides ; Azides ; Nitro compounds ; Azo compounds ; Triazenes ; Nitrates and nitrites ; N-nitroso compounds ; N-oxides ; Alcohols ; Phenols ; Ethers ; Epoxides ; Peroxides ; Thiols ; Thioethers ; Sulfoxides ; Sulfones ; Aliphatic amines ; Quaternary ammonium salts ; Amidines ; Guanidines, acylguanidines, and biguanides ; Anilines ; Hydrazines, acylhydrazines, and hydrazones ; Aldehydes ; Ketones ; Carboxylic acids ; Carboxylic esters ; Amides ; Lactams and imides ; Nitriles ; Carbonates ; Carbamates ; Ureas ; Thiocarbonyl compounds ; Sulfonic acids ; Sulfonic esters ; Sulfates And sulfamic acids ; Phosphonic acids ; Phosphoric acid derivatives ; N-(aminoalkyl)benzamides, -benzoates, and related compounds ; Arylalkylamines ; Phenethylamines (2-phenylethylamines) ; Aminoalkylindoles and indole alkaloids ; Phenothiazines ; Dibenzazepines and related tricyclic compounds ; 3-aryloxy-2-hydroxypropylamines (b-adrenergic antagonists; 'b-blockers') ; Opiates ; N-(carboxyalkyl)-a-amino acid amides (prils) ; Anilides and amides of glycine ; Peptides, peptidomimetics, and related oligoamides ; Oligoarylamines, oligoarylamides, oligoarylcarbamates, and oligoarylureas ; Imidazoles ; Triazoles ; Pyridines, pyrimidines, and related compounds ; Quinolines ; Nucleoside analogs ; Dihydropyridines ; Arenesulfonamides ; Sulfonylureas ; Benzodiazepines ; Steroids ; Anthracyclines ; Arylacetic, benzoic, and related carboxylic acids (NSAIDS) ; Quinolonecarboxylic acids (gyrase inhibitors) ; B-lactams ; Prostaglandin analogs ; Sartans ; Statins ; Folic acid analogs (antifolates) ; Taxanes ; Macrocyclic compounds.…”
Available online from ProQuest Ebook Central - Academic Complete: 2012

Current advances in osteosarcoma : clinical perspectives : past, present and future

Table of Contents: “…Lindsey -- Discovery of cell-surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL12 immune therapy / Izhar S. batth and Shulin Li -- part. 4. Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention / Anchit Bhagat and Eugenie S. …”
Connect to this title online (unlimited simultaneous users allowed; 325 uses per year)

Hot topics in cardio-oncology

Table of Contents: “…List of Figures ix List of Tables xi List of Contributors xiii List of Abbreviations xvii Introduction xxi 1 Inflammation in Cardio-Oncology 1 1.1 Introduction 2 1.2 Inflammation in Cardiac Injury and Repair 2 1.3 Immune Checkpoint Inhibitors 4 1.4 CAR-T Cell Therapy 8 1.5 Inflammation at the Crossroad Between Cancer and Cardiovascular Diseases 9 References 12 2 Vascular Toxicity and Thromboembolic Risk in Cardio-Oncology 21 2.1 Introduction 21 2.2 Acute Coronary Syndrome (ACS) and Coronary Artery Diseases (CAD) 22 2.3 Other Drugs that Cause Myocardial Infarction and Coronary Artery Diseases 25 2.4 Arterial Hypertension 27 2.5 Peripheral Artery Occlusive Diseases 28 2.6 Pulmonary Hypertension 29 2.7 Stroke 29 2.8 Thromboembolic Risk and Atrial Fibrillation 30 2.9 Prevention and Treatment of Vascular Toxicity 31 References 32 3 Hypertensive Oncologic Patients 41 3.1 Introduction 41 3.2 Implications of Arterial Hypertension in Patients Undergoing Anticancer Treatments 42 3.2.1 Anthracyclines 42 3.2.2 Carfilzomib 42 3.2.3 Anti-vascular endothelial growth factor agents 43 3.3 Management of Arterial Hypertension in Oncologic Patients 44 References 47 4 Cardiac Surgery and Percutaneous Coronary Intervention in Patients With Cancer 51 4.1 Introduction 51 4.1.1 The complex interplay between ACS and cancer: bench and pharmacological data 51 4.1.2 The complex interplay between ACS and cancer: the role of the disease 52 4.1.3 The complex interplay between ACS and cancer: the role of chemotherapy and of radiotherapy 53 4.1.4 The complex interplay between ACS and cancer: clinical data 55 4.1.5 The complex interplay between cardiac surgery and cancer: clinical data 57 References 58 5 Cancer Therapy-Induced Arrhythmias 63 5.1 Introduction 63 5.1.1 Epidemiology 63 5.1.2 Etiology and Pathogenesis 64 5.1.3 Diagnosis, Physical Examination, and Diagnostic Tests 67 5.1.4 Clinical Characteristics 69 5.1.5 Treatment 69 5.1.6 Prophylaxis 76 References 78 6 Cancer in the Heart Failure Population 83 6.1 Introduction 84 6.2 Heart Failure and New Onset Cancer: Epidemiology 84 6.3 Mechanisms of Cancer Development in the Heart Failure Population 87 6.4 Cancer in Heart Failure Patients: Clinical Implications 91 6.5 Conclusions 96 References 97 7 Metabolomics in the Identification of New Biomarkers in Cardio-Oncology 107 7.1 Introduction 107 7.2 Metabolomics 108 7.3 Metabolomics in Cardio-Oncology 110 7.4 Metabolomics Profiling Cardioprotective Strategies 114 7.5 Conclusion 115 References 116 8 Imaging in Cardio-Oncology 121 8.1 Introduction 121 8.2 Conventional Echocardiography 122 8.2.1 LV systolic and diastolic function 122 8.2.2 RV function 124 8.2.3 Valvular heart disease 125 8.2.4 Pericardial disease 126 8.3 Advanced Echocardiography 127 8.3.1 Myocardial deformation imaging 127 8.4 Three-Dimensional Echocardiography (3DE) 129 8.5 Assessment of Cardiotoxicity Risk and Echocardiographic Surveillance According to Anticancer Treatment 129 8.6 Other imaging modalities 133 8.6.1 Cardiac Magnetic Resonance 133 8.7 Cardiac Nuclear Imaging 135 8.8 Multimodality Imaging in Screening and Follow-up in Radiotherapy 136 8.8.1 Pericardial disease 136 8.8.2 Myocardial dysfunction 136 8.8.3 Valvular heart disease (see also above) 137 8.8.4 Coronary artery disease 137 8.9 Conclusions and Future Directions 138 References 139 9 Venous Thromboembolism in Cardio-Oncology 147 9.1 Introduction 147 9.2 Biological Mechanism of Cancer-Related Thrombosis 148 9.3 Epidemiology and Risk Stratification 148 9.4 Clinical Presentation 151 9.5 Recurrent Venous Thrombosis and Treatment in Cancer Population 153 9.6 Prognosis 155 9.7 Thromboprophylaxis 155 9.8 Conclusions 156 References 157 Conclusions and Remarks 163 References 164 Index 165 About the Editors 167.…”
Available online from ProQuest Ebook Central - Academic Complete: 2021